CJC-1295 5mg + Ipamorelin 5mg

Peptide Profile

CJC-1295 + Ipamorelin is a dual-action peptide combination frequently studied for its synergistic stimulation of endogenous growth hormone (GH) secretion. By pairing a Growth Hormone–Releasing Hormone (GHRH) analogue with a Growth Hormone Secretagogue (GHS), this blend enables a more natural, pulse-like release of GH in laboratory models.

CJC-1295, a tetrasubstituted GHRH analogue, is engineered for prolonged half-life and stable GH-releasing activity, promoting extended interaction with pituitary receptors.
Ipamorelin, a selective GHS, complements this effect by enhancing GH release through ghrelin-receptor pathways—without significantly altering prolactin, cortisol, or ACTH levels.

Researchers value this synergistic pairing for its potential to support studies on cellular repair, tissue regeneration, lipid metabolism, and recovery signaling. It is also frequently utilized in endocrine and longevity research to investigate GH/IGF-1 axis modulation and metabolic efficiency.

Key Highlights

• Synergistic peptide pairing: CJC-1295 (GHRH analogue) + Ipamorelin (GHS)
• Studied for endogenous GH release, tissue recovery, and metabolic signaling
• Long-acting, high-purity formulation engineered for stability and precision
• Manufactured under stringent quality and sterility controls
• For laboratory research use only